View Item 

Show simple item record

Therapeutically interchangeable? A study of real‐world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data
dc.contributor.authorLevin, P.en_US
dc.contributor.authorWei, W.en_US
dc.contributor.authorMiao, R.en_US
dc.contributor.authorYe, F.en_US
dc.contributor.authorXie, L.en_US
dc.contributor.authorBaser, O.en_US
dc.contributor.authorGill, J.en_US
dc.date.accessioned2015-03-05T18:24:39Z
dc.date.available2016-05-10T20:26:27Zen
dc.date.issued2015-03en_US
dc.identifier.citationLevin, P.; Wei, W.; Miao, R.; Ye, F.; Xie, L.; Baser, O.; Gill, J. (2015). "Therapeutically interchangeable? A study of real‐world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data." Diabetes, Obesity and Metabolism 17(3): 245-253.en_US
dc.identifier.issn1462-8902en_US
dc.identifier.issn1463-1326en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110746
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherpersistenceen_US
dc.subject.otherswitchingen_US
dc.subject.othertype 2 diabetesen_US
dc.subject.otheradherenceen_US
dc.subject.othercosten_US
dc.subject.otherhypoglycaemiaen_US
dc.subject.otherinsulin detemiren_US
dc.subject.otherinsulin glargineen_US
dc.titleTherapeutically interchangeable? A study of real‐world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records dataen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Health (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110746/1/dom12407.pdf
dc.identifier.doi10.1111/dom.12407en_US
dc.identifier.sourceDiabetes, Obesity and Metabolismen_US
dc.identifier.citedreferenceQuan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD‐9‐CM and ICD‐10 administrative data. Med Care 2005; 43: 1130 – 1139.en_US
dc.identifier.citedreferenceInzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient‐centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577 – 1596.en_US
dc.identifier.citedreferenceHollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52‐week, multinational, open‐label, parallel‐group, noninferiority, treat‐to‐target trial comparing insulin detemir with insulin glargine in a basal‐bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008; 30: 1976 – 1987.en_US
dc.identifier.citedreferenceSwinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; 7: CD006383.en_US
dc.identifier.citedreferenceRosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52‐week, treat‐to‐target trial comparing insulin detemir with insulin glargine when administered as add‐on to glucose‐lowering drugs in insulin‐naive people with type 2 diabetes. Diabetologia 2008; 51: 408 – 416.en_US
dc.identifier.citedreferenceMeneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P. Once‐daily initiation of basal insulin as add‐on to metformin: a 26‐week, randomized, treat‐to‐target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 729 – 736.en_US
dc.identifier.citedreferenceKing AB. Once‐daily insulin detemir is comparable to once‐daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double‐blind, randomized, crossover study. Diabetes Obes Metab 2009; 11: 69 – 71.en_US
dc.identifier.citedreferenceDavis KL, Tangirala M, Meyers JL, Wei W. Real‐world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. Curr Med Res Opin 2013; 29: 1083 – 1091.en_US
dc.identifier.citedreferenceBorah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin‐naive patients with type 2 diabetes. Clin Ther 2009; 31: 623 – 631.en_US
dc.identifier.citedreferenceMcAdam‐Marx C, Bouchard J, Aagren M, Nelson R, Brixner D. Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting. Diabetes Obes Metab 2010; 12: 54 – 64.en_US
dc.identifier.citedreferenceYenigun M, Honka M. Switching patients from insulin glargine‐based basal‐bolus regimens to a once daily insulin detemir‐based basal‐bolus regimen: results from a subgroup of the PREDICTIVE study. Int J Clin Pract 2009; 63: 425 – 432.en_US
dc.identifier.citedreferenceLüddeke HJ, Sreenan S, Aczel S et al. PREDICTIVE‐a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007; 9: 428 – 434.en_US
dc.identifier.citedreferenceBryant GA, McDanel DL, Horner KE, Farris KB, Newkirk EN. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir. Pharmacotherapy 2013; 33: 56 – 62.en_US
dc.identifier.citedreferenceWei W, Zhou S, Miao R et al. Much ado about nothing? A real‐world study of patients with type 2 diabetes switching basal insulin analogs. Adv Ther 2014; 31: 539 – 560.en_US
dc.identifier.citedreferenceCharlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373 – 383.en_US
dc.identifier.citedreferenceXie L, Wei W, Pan C, Du J, Baser O. A real‐world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther 2011; 28: 1000 – 1011.en_US
dc.identifier.citedreferenceGinde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD‐9‐CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord 2008; 8: 4.en_US
dc.identifier.citedreferenceWei W, Pan C, Xie L, Baser O. Real‐world insulin treatment persistence among patients with type 2 diabetes. Endocr Pract 2014; 20: 52 – 61.en_US
dc.identifier.citedreferenceRassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One‐to‐many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf 2012; 21 (Suppl. 2): 69 – 80.en_US
dc.identifier.citedreferenceNiven DJ, Berthiaume LR, Fick GH, Laupland KB. Matched case‐control studies: a review of reported statistical methodology. Clin Epidemiol 2012; 4: 99 – 110.en_US
dc.identifier.citedreferenceAustin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples. Stat Med 2009; 28: 3083 – 3107.en_US
dc.identifier.citedreferenceStevens J, Truesdale KP, McClain JE, Cai J. The definition of weight maintenance. Int J Obes (Lond) 2006; 30: 391 – 399.en_US
dc.identifier.citedreferenceAbalı S, Turan S, Atay Z, Güran T, Haliloğlu B, Bereket A. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus. Pediatr Diabetes 2014; DOI: 10.1111/pedi.12167.en_US
dc.identifier.citedreferenceKabadi UM. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus. Clin Drug Investig 2008; 28: 697 – 701.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
dom12407.pdf
Size:
885.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.